S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in
NASDAQ:VTGN

VistaGen Therapeutics Competitors

$2.41
-0.06 (-2.43 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.38
Now: $2.41
$2.58
50-Day Range
$1.89
MA: $2.25
$2.96
52-Week Range
$0.30
Now: $2.41
$3.18
Volume2.69 million shs
Average Volume4.83 million shs
Market Capitalization$341.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52

Competitors

VistaGen Therapeutics (NASDAQ:VTGN) Vs. BTAI, MRSN, RYTM, ARCT, PHAT, and CNST

Should you be buying VTGN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to VistaGen Therapeutics, including BioXcel Therapeutics (BTAI), Mersana Therapeutics (MRSN), Rhythm Pharmaceuticals (RYTM), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT), and Constellation Pharmaceuticals (CNST).

BioXcel Therapeutics (NASDAQ:BTAI) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

48.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are held by institutional investors. 9.4% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for BioXcel Therapeutics and VistaGen Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioXcel Therapeutics00903.00
VistaGen Therapeutics00403.00

BioXcel Therapeutics currently has a consensus target price of $102.00, indicating a potential upside of 83.09%. VistaGen Therapeutics has a consensus target price of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than BioXcel Therapeutics.

Profitability

This table compares BioXcel Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioXcel TherapeuticsN/A-74.22%-64.31%
VistaGen TherapeuticsN/AN/A-272.12%

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioXcel Therapeutics and VistaGen Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-27.58
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82

BioXcel Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

VistaGen Therapeutics beats BioXcel Therapeutics on 6 of the 10 factors compared between the two stocks.

Mersana Therapeutics (NASDAQ:MRSN) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Mersana Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mersana Therapeutics-8,772.91%-45.16%-37.53%
VistaGen TherapeuticsN/AN/A-272.12%

Analyst Ratings

This is a summary of recent recommendations and price targets for Mersana Therapeutics and VistaGen Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mersana Therapeutics01502.83
VistaGen Therapeutics00403.00

Mersana Therapeutics currently has a consensus price target of $27.80, indicating a potential upside of 40.55%. VistaGen Therapeutics has a consensus price target of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Mersana Therapeutics.

Earnings & Valuation

This table compares Mersana Therapeutics and VistaGen Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mersana Therapeutics$42.12 million32.17$-28,210,000.00($0.65)-30.43
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82

VistaGen Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. 5.3% of Mersana Therapeutics shares are held by company insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

VistaGen Therapeutics beats Mersana Therapeutics on 9 of the 13 factors compared between the two stocks.

VistaGen Therapeutics (NASDAQ:VTGN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and price targets for VistaGen Therapeutics and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VistaGen Therapeutics00403.00
Rhythm Pharmaceuticals01502.83

VistaGen Therapeutics currently has a consensus price target of $5.6667, indicating a potential upside of 135.13%. Rhythm Pharmaceuticals has a consensus price target of $50.00, indicating a potential upside of 86.29%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Rhythm Pharmaceuticals.

Insider & Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares VistaGen Therapeutics and Rhythm Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-6.95

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VistaGen Therapeutics and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VistaGen TherapeuticsN/AN/A-272.12%
Rhythm PharmaceuticalsN/A-55.21%-50.73%

Summary

VistaGen Therapeutics beats Rhythm Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Arcturus Therapeutics and VistaGen Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
VistaGen Therapeutics00403.00

Arcturus Therapeutics presently has a consensus target price of $73.0769, indicating a potential upside of 33.74%. VistaGen Therapeutics has a consensus target price of $5.6667, indicating a potential upside of 135.13%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Arcturus Therapeutics.

Earnings and Valuation

This table compares Arcturus Therapeutics and VistaGen Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million64.37$-25,990,000.00($2.15)-25.41
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82

VistaGen Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arcturus Therapeutics and VistaGen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
VistaGen TherapeuticsN/AN/A-272.12%

Volatility & Risk

Arcturus Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Summary

VistaGen Therapeutics beats Arcturus Therapeutics on 8 of the 12 factors compared between the two stocks.

VistaGen Therapeutics (NASDAQ:VTGN) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for VistaGen Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VistaGen Therapeutics00403.00
Phathom Pharmaceuticals10402.60

VistaGen Therapeutics currently has a consensus price target of $5.6667, suggesting a potential upside of 135.13%. Phathom Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 14.84%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Phathom Pharmaceuticals.

Earnings and Valuation

This table compares VistaGen Therapeutics and Phathom Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-3.30

VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VistaGen Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VistaGen TherapeuticsN/AN/A-272.12%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Volatility & Risk

VistaGen Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

VistaGen Therapeutics (NASDAQ:VTGN) and Constellation Pharmaceuticals (NASDAQ:CNST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for VistaGen Therapeutics and Constellation Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VistaGen Therapeutics00403.00
Constellation Pharmaceuticals02602.75

VistaGen Therapeutics currently has a consensus price target of $5.6667, suggesting a potential upside of 135.13%. Constellation Pharmaceuticals has a consensus price target of $46.00, suggesting a potential upside of 71.64%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Constellation Pharmaceuticals.

Insider and Institutional Ownership

3.1% of VistaGen Therapeutics shares are held by institutional investors. 13.7% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares VistaGen Therapeutics and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VistaGen TherapeuticsN/AN/A-272.12%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Volatility & Risk

VistaGen Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500.

Earnings and Valuation

This table compares VistaGen Therapeutics and Constellation Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-4.82
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-8.82

Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

VistaGen Therapeutics beats Constellation Pharmaceuticals on 8 of the 11 factors compared between the two stocks.


VistaGen Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$55.71-3.8%$1.36 billionN/A-16.53Upcoming Earnings
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.6$19.78-8.1%$1.35 billion$42.12 million-14.65Earnings Announcement
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.7$26.84-3.4%$1.34 billionN/A-8.83Earnings Announcement
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.8$54.64-3.6%$1.34 billion$20.79 million-18.84Earnings Announcement
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.6$46.15-4.6%$1.34 billionN/A-3.30
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$26.80-6.0%$1.28 billionN/A-9.89Earnings Announcement
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$50.06-3.0%$1.28 billionN/A-208.58Decrease in Short Interest
Gap Down
PLRX
Pliant Therapeutics
1.7$35.47-6.7%$1.26 billion$57.05 million0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.70-6.1%$1.25 billionN/A0.00Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.62-2.1%$1.24 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Avid Bioservices logo
CDMO
Avid Bioservices
1.4$21.77-5.5%$1.23 billion$59.70 million-217.70Upcoming Earnings
News Coverage
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$11.69-2.9%$1.20 billion$120,000.00-4.33Upcoming Earnings
Omeros logo
OMER
Omeros
1.2$19.41-2.7%$1.20 billion$111.81 million-8.16Earnings Announcement
Gap Down
Zogenix logo
ZGNX
Zogenix
1.7$20.95-1.2%$1.17 billion$3.65 million-2.20Earnings Announcement
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.40-0.3%$1.16 billion$261.02 million5.82News Coverage
Annexon logo
ANNX
Annexon
1.7$29.91-2.7%$1.14 billionN/A0.00News Coverage
Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.26-1.3%$1.13 billion$150,000.00-7.51Earnings Announcement
Analyst Downgrade
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$17.48-5.2%$1.12 billion$73.41 million-3.70Analyst Report
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.5$35.67-9.2%$1.10 billionN/A0.00Upcoming Earnings
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.5$30.59-0.6%$1.06 billionN/A-14.10
Veru logo
VERU
Veru
1.4$14.41-4.1%$1.04 billion$42.59 million-51.46Increase in Short Interest
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$24.06-7.4%$1.03 billion$4.23 million-17.82Earnings Announcement
Increase in Short Interest
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.74-0.5%$1.03 billion$227.19 million52.06
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$13.75-0.5%$1.03 billion$40.89 million-4.74Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.75-11.9%$1.02 billion$230,000.00-12.44Upcoming Earnings
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.73-0.8%$1.00 billion$122.47 million-27.32
Epizyme logo
EPZM
Epizyme
1.7$9.78-1.9%$995.46 million$23.80 million-4.39
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$24.15-1.1%$986.99 million$1.52 million-12.85
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.90-1.7%$980.54 million$35.22 million-6.50Earnings Announcement
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.07-4.2%$967.99 millionN/A-7.96Earnings Announcement
Analyst Revision
Gap Down
Humanigen logo
HGEN
Humanigen
1.7$18.49-0.5%$954.40 millionN/A0.00Upcoming Earnings
Insider Selling
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$18.91-3.0%$942.32 million$19.89 million-8.92Earnings Announcement
MannKind logo
MNKD
MannKind
1.4$4.01-42.4%$932.73 million$63.04 million-19.09High Trading Volume
Gap Up
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$22.78-5.3%$921.52 million$800.40 million21.49
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$7.60-5.4%$921.00 million$322.07 million-7.24News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.3$23.43-5.1%$891.23 million$14.87 million-8.74
Radius Health logo
RDUS
Radius Health
1.1$18.96-1.8%$882.53 million$173.32 million-7.77Earnings Announcement
Analyst Report
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.62-6.9%$876.23 million$2.22 million-21.29Upcoming Earnings
Analyst Revision
News Coverage
Gap Down
ESSA Pharma logo
EPIX
ESSA Pharma
1.1$26.95-0.5%$864.13 millionN/A-24.95Increase in Short Interest
Prothena logo
PRTA
Prothena
2.1$21.49-3.9%$857.90 million$810,000.00-8.39
Kadmon logo
KDMN
Kadmon
2.0$4.95-7.3%$848.99 million$5.09 million-8.25Upcoming Earnings
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.48-0.3%$830.37 million$322.36 million124.86
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.71-4.3%$804.87 millionN/A0.00Upcoming Earnings
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$28.52-4.0%$796.93 million$148.36 million-7.41Gap Down
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.93-2.9%$792.97 million$296.70 million46.80Earnings Announcement
AnaptysBio logo
ANAB
AnaptysBio
1.1$28.05-2.3%$767.11 million$8 million-10.35Earnings Announcement
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.47-7.2%$755.35 million$59.29 million-29.80Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.94-5.4%$754.72 millionN/A-2.79Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.4$23.83-5.6%$753.10 million$31.13 million-7.76News Coverage
Gap Down
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$19.35-8.8%$746.99 millionN/A-4.94Earnings Announcement
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.